Filana Therapeutics, Inc. Common Stock (FLNA) is a publicly traded the market company. As of May 21, 2026, FLNA trades at $1.23 with a market cap of $57.49M and a P/E ratio of 0.00. FLNA moved +4.58% today. Year to date, FLNA is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $1.16 to $2.27. Rallies surfaces FLNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Filana Advances Simufilam with Preclinical Epilepsia Data, Q1 Cash at $86.6M: Filana Therapeutics ended Q1 with $86.6M cash, no debt and forecasts $47-50M by June 30 after net operating cash burn of $8.9M, while reducing R&D and G&A expenses by 67% and 39% year-over-year following Alzheimer’s program phase-out. The company is advancing simufilam for TSC-related epilepsy, published preclinical Epilepsia data showing dose-dependent seizure attenuation in mice and plans to resolve FDA’s clinical hold with additional studies and protocol revisions.
| Metric | Value |
|---|---|
| Price | $1.23 |
| Market Cap | $57.49M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.27 |
| 52-Week Low | $1.16 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
FLNA analyst coverage data. Average price target: $0.00.